[
  {
    "ts": null,
    "headline": "5 Insightful Analyst Questions From Zoetis’s Q1 Earnings Call",
    "summary": "Zoetis delivered revenue and adjusted EPS above Wall Street expectations in Q1, driven by strong organic operational growth across its diverse portfolio. Management pointed to particularly robust performance internationally, with the Simparica, dermatology, and osteoarthritis pain franchises fueling momentum. CEO Kristin Peck highlighted, “our innovative companion animal portfolio grew 9% operationally, fueled by sustained demand for our diverse, market-leading franchises.” Despite ongoing macro",
    "url": "https://finnhub.io/api/news?id=d7cfdb9d7af25308082650e6ff1a22aac50066398b82b9d3430d32f523cd2333",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750975370,
      "headline": "5 Insightful Analyst Questions From Zoetis’s Q1 Earnings Call",
      "id": 135586337,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "Zoetis delivered revenue and adjusted EPS above Wall Street expectations in Q1, driven by strong organic operational growth across its diverse portfolio. Management pointed to particularly robust performance internationally, with the Simparica, dermatology, and osteoarthritis pain franchises fueling momentum. CEO Kristin Peck highlighted, “our innovative companion animal portfolio grew 9% operationally, fueled by sustained demand for our diverse, market-leading franchises.” Despite ongoing macro",
      "url": "https://finnhub.io/api/news?id=d7cfdb9d7af25308082650e6ff1a22aac50066398b82b9d3430d32f523cd2333"
    }
  }
]